Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-尾 (A尾) immunotherapies. Several assays for measuring phosphorylated tau (p-tau...
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau...
Blood biomarkers Palabras clave Demencia Enfermedad de Alzheimer Diagnóstico precoz Biomarcadores sanguíneos Introduction Alzheimer disease (AD) is the most frequent neurodegenerative disease, causing 50%–70% of all cases of dementia1, 2, 3, 4, 5, 6, 7; the disease is expected to affect up ...
Introduction: Concerns have been raised about the limited health system capacity for identification of patients who are eligible for a disease-modifying Alzheimer's treatment (DMT). Blood-based biomarker (BBBM) tests are a promising tool to improve triaging at the primary care level. We projected...
et al. Alzheimer’s disease. Lancet 388, 505–517 (2016). CAS PubMed Google Scholar Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673–684 (2016). CAS PubMed Google Scholar Lista, S...
Blood biomarkers have shown to be simple, non-invasive, and patient-friendly in early AD diagnosis, Yu said, emphasizing the importance of the study. Plasma GFAP has emerged as a biomarker in neurological disorders, but its usefulness for AD diagnosis and prediction remained unclear. This study ...
US CTAD Task Force on “what must be done” to move blood-based biomarkers (BBMs) of Alzheimer's disease (AD) from research to use in clinical practice. There is little doubt that «timely and accurate diagnosis of Alzheimer's disease in clinical practice» (1) is an important goal....
Blood-based biomarkers for Alzheimer′s disease: towards clinical implementa-tion[J]. The Lancet Neurology, 2022, 21(1): 66 – 77. DOI: 10.1016/S1474-4422(21)00361-6 [7] Hampel H, O′Bryant SE, Molinuevo JL, et al. Blood-based bio-markers for Alzheimer disease: mapping the road...
Introduction Efforts to find reliable blood biomarkers for Alzheimer's disease (AD) in a highly warranted clinical laboratory test have met with little suc... H Zetterberg,D Wilson,U Andreasson,... - 《Alzheimers Research & Therapy》 被引量: 166发表: 2013年 Cerebrospinal Fluid Biomarkers for ...
Our understanding of the molecular genetic basis of two common neurodegenerative dementias, Alzheimer's disease (AD) and frontotemporal lobar degeneration ... R Rademakers,A Rovelet-Lecrux - 《Trends in Neurosciences》 被引量: 228发表: 2009年 Vascular dementia: still a debatable entity? Vascular ...